Corbus Pharmaceuticals 的 CRB-701 1 期试验显示 nectin-4 阳性肿瘤的阳性数据，导致股价飙升 256%。 Corbus Pharmaceuticals' CRB-701 Phase 1 trial shows positive data for nectin-4 positive tumors, causing shares to surge 256%.

Corbus Pharmaceuticals (CRBP) 报告了其抗体药物偶联物 CRB-701 在 nectin-4 阳性肿瘤患者中进行的 1 期试验的阳性数据。 Corbus Pharmaceuticals (CRBP) reported positive data from a Phase 1 trial of its antibody-drug conjugate CRB-701 in patients with nectin-4 positive tumors. 结果，该公司股价周五飙升超过 256%，并将在 2024 年美国临床肿瘤学会泌尿生殖系统癌症研讨会上公布这一结果。 As a result, shares of the company surged by more than 256% on Friday, and were set to present the results at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium.